Patents Represented by Attorney Michael P. Morris

Find this attorney in the Justia Lawyer Directory

  • Cyanopyrimidinones
    Patent number: 8088769
    Abstract: The invention relates to novel cyanopyrimidinones, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory.
    Type: Grant
    Filed: December 31, 2004
    Date of Patent: January 3, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Hendrix, Lars Bärfacker, Heike Heckroth, Dagmar Karthaus, Adrian Tersteegen
  • Method for checking the permeability rate of a closed container
    Patent number: 8087286
    Abstract: In a method for checking the permeability rate of a closed container (3) with respect to a medium, in particular for checking the permeability rate of a film-type container for accommodating a film container for accommodating a pharmaceutical active constituent formulation, the container (3) is filled with a medium, charged with a gas, and the increase in the amount of medium in the gas is then analysed.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: January 3, 2012
    Assignee: Boehringer Ingelheim International, GmbH
    Inventors: Daniela Bothe, Hubert Hoelz, Christoph Kreher, Burkhard Metzger, Christian Scheffler
  • Production method
    Patent number: 8084634
    Abstract: The present invention relates to a process for preparing compounds of general formula I wherein R1 and R2 are defined as in claim 1, the pharmaceutically acceptable salts and the solvates thereof, which may be prepared starting from compounds of general formula II wherein R1 is defined as in claim 1.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: December 27, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Guenther Huchler, Werner Rall, Uwe Reis
  • Viral polymerase inhibitors
    Patent number: 8076365
    Abstract: The present invention relates to compounds represented by formula (I) wherein A, B, D, E, R2, R3, R4, R5, R6, R9, a, b, d and e are as defined herein, their salt or ester and pharmaceutical compositions thereof useful in the treatment of hepatitis C viral (HCV) infection. Said compounds were found to have inhibitory activity against HCV polymerase, especially as inhibitors of HCV NS5B polymerase.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: December 13, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Youla S. Tsantrizos
  • Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
    Patent number: 8071583
    Abstract: The present invention relates to substituted pyrrolo[3,2-d]pyrimidines of formula (I), wherein R1 and R2 are defined as in claim 1, including the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: December 6, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Frank Himmelsbach
  • Process for preparing aminocrotonylamino-substituted quinazoline derivatives
    Patent number: 8067593
    Abstract: The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: November 29, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Schroeder, Georg Dziewas
  • Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds
    Patent number: 8067590
    Abstract: The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: November 29, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Joerg Kley, Klaus Rudolf, Armin Heckel, Marcus Schindler, Ralf Lotz, Thorsten Lehmann-Lintz
  • Hepatitis C inhibitor compounds
    Patent number: 8067438
    Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: November 29, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Montse Llinas-Brunet, Murray Douglas Bailey, Punit R. Bhardwaj, Josee Bordeleau, Pasquale Forgione, Elise Ghiro, Vida J. Gorys, Nathalie Goudreau, Sylvie Goulet, Teddy Halmos, Jean Rancourt
  • Indolinone derivatives and process for their manufacture
    Patent number: 8067617
    Abstract: The present invention relates to specific indolinone derivatives, namely the compounds of formula, in which R1 represents an hydrogen atom or a group, and R2 and R3 each represent an hydrogen atom or R2 and R3 taken together represent a group, with the proviso that when R1 represents an hydrogen atom R2 and R3 taken together represent a group, and to a process for their manufacture.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: November 29, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joern Merten, Svenja Renner, Carsten Reichel
  • Anti-cytokine heterocyclic compounds
    Patent number: 8063094
    Abstract: Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Denise Andersen, Tina Marie Morwick, Roger John Snow, Yancey David Ward
  • Azaindazole compounds as CCR1 receptor antagonists
    Patent number: 8063065
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Darren Di Salvo, Christian Harcken, Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, Can Mao, Jochen Neu, Brian Christopher Raudenbush, Hossein Razavi, Alan David Swinamer
  • Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
    Patent number: 8062626
    Abstract: The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim KG
    Inventors: Bernhard Freund, Michael Krueger, Bernd Zierenberg
  • Hybridoma producing antibodies to
    Patent number: 8058062
    Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: November 15, 2011
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventor: Malik Merza
  • Dihydropteridinones for the treatment of cancer diseases
    Patent number: 8058270
    Abstract: Disclosed is the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: November 15, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerd Munzert, Martin Steegmaier
  • Compounds which selectively modulate the CB2 receptor
    Patent number: 8048899
    Abstract: are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 1, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Angela Berry, Eugene Richard Hickey, Markus Ostermeier, Doris Riether, Achim Sauer, David Smith Thomson, Lifen Wu, Renee M. Zindell, Patricia Amouzegh, Nigel James Blumire, Stephen Peter East, Monika Ermann, Someina Khor, Innocent Mushi
  • Medicaments for the treatment of chronic obstructive pulmonary disease
    Patent number: 8044046
    Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: October 25, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co KG
    Inventors: Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Frank Buettner, Claudia Heine, Philipp Lustenberger, Christoph Hoenke, Klaus Rudolf
  • 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
    Patent number: 8044060
    Abstract: Described are 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolo[3,4-d]pyrimidines of the formula (I): as defined herein, processes for their preparation and their use for producing medicaments for treating impairment of perception, concentration, learning and/or memory.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: October 25, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Hendrix, Lars Bärfacker, Christina Erb, Frank-Thorsten Hafner, Heike Heckroth, Dagmar Karthaus, Adrian Tersteegen, Franz-Josef van der Staay, Marja van Kampen
  • Inhibitors of HIV replication
    Patent number: 8039638
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: October 18, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christiane Yoakim, Patrick Deroy, Martin Duplessis, Alexandre Gagnon, Sylvie Goulet, Oliver Hucke, Christopher Lemke, Simon Suprenant
  • Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
    Patent number: 8039441
    Abstract: Glucopyranosyl-substituted cyclopropyl-benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: October 18, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann
  • Substituted pyrazolo[3,4-d]pyrimidin-4-one compounds as phosphodiesterase inhibitors
    Patent number: 8039477
    Abstract: The invention relates to novel alkyl-substituted pyrazolopyrimidines, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory with compounds of formula (I):
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: October 18, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Hendrix, Frank-Gerhard Böβ, Nils Burkhardt, Christina Erb, Adrian Tersteegen, Marja Van Kampen